Should I buy or sell Epigral?

The average broker rating on Epigral is Strong Buy. The breakup of analyst rating is given below - 0.00 analysts have given a strong sell rating 0.00 analysts have given a sell rating 0.00 analysts have given a hold rating 0.00 analysts have given a buy rating 1 analysts have given a strong buy rating

Is Epigral a good stock to invest in?

Epigral can be analyzed on the following key metrics - TTM P/E: 22.82 Sector P/E: 17.23 Dividend Yield: 0.41% D/E ratio: -

Epigral Share Price

Sector: Chemical Manufacturing

Powered by

1750.20 -71.15 (-3.91%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 1750.20

Today’s High 1813.90

52 Week Low 1107.45

52 Week High 2408.35

Key Metrics

Market Cap (In Cr) 7569.57
Beta 1.56
Div. Yield (%) 0.41
P/B 6.04
TTM P/E 22.82
Peg Ratio 0.89
Sector P/E 17.23
Open Price 1806.05
Prev Close 1821.35

View All Metrics

Epigral Analysis

Price Analysis

1 Week

-6.54%
3 Months

3.71%
6 Month

-8.82%
YTD

-3.87%
1 Year

38.61%

Risk Meter

52% Low risk
52% Moderate risk
52% Balanced Risk
52% High risk
52% Extreme risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings
Current
1 W Ago
1 M Ago
3 M Ago

Strong Buy
1
1
1
1

Buy
0.00
0.00
0.00
0.00

Hold
0.00
0.00
0.00
0.00

Sell
0.00
0.00
0.00
0.00

Strong Sell
0.00
0.00
0.00
0.00

Total
1
1
1
1

Epigral News

Multibagger Stock: Epigral yielded 120% return in a year, 432% in over 3 years. (Pixabay)

Premium

Multibagger Stock: Epigral yields 120% return in a year, 430% in over 3 years

1 min read . 18 Nov 2024

Stock market today: Sumeet Bagadia has recommended a specific strategy in the current market conditions (MINT)

Premium

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy

3 min read . 11 Sep 2024

Premium

Epigral Q1 Results Live : profit rise by 172.54% YOY

1 min read . 25 Jul 2024

Nirmal Bang predicts Nifty to trade in the range of 22,000-23,000 for the May Series.

Premium

Stocks to buy in May: Nirmal Bang suggests Epigral and Suryoday SFB

3 min read . 07 May 2024

View More News

Epigral Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
1929.19

Selling/ General/ Admin Expenses Total
127.16

Depreciation/ Amortization
123.56

Other Operating Expenses Total
99.19

Total Operating Expense
1570.85

Operating Income
358.34

Net Income Before Taxes
290.75

Net Income
195.87

Diluted Normalized EPS
47.15

Period
2023

Total Revenue
2188.4

Selling/ General/ Admin Expenses Total
115.66

Depreciation/ Amortization
108.95

Other Operating Expenses Total
90.84

Total Operating Expense
1605.88

Operating Income
582.52

Net Income Before Taxes
522.46

Net Income
353.29

Diluted Normalized EPS
85.03

Period
2022

Total Revenue
1550.94

Selling/ General/ Admin Expenses Total
94.09

Depreciation/ Amortization
85.91

Other Operating Expenses Total
104.83

Total Operating Expense
1127.29

Operating Income
423.65

Net Income Before Taxes
383.42

Net Income
252.79

Diluted Normalized EPS
60.85

Period
2021

Total Revenue
828.6

Selling/ General/ Admin Expenses Total
58.31

Depreciation/ Amortization
73.54

Other Operating Expenses Total
92.04

Total Operating Expense
640.81

Operating Income
187.79

Net Income Before Taxes
160.86

Net Income
100.84

Diluted Normalized EPS
24.27

Period
2020

Total Revenue
610.51

Selling/ General/ Admin Expenses Total
48.54

Depreciation/ Amortization
44.3

Other Operating Expenses Total
64.02

Total Operating Expense
460.25

Operating Income
150.25

Net Income Before Taxes
140.99

Net Income
112

Diluted Normalized EPS
26.96

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Epigral Technical

Moving Average SMA

5 Day1896.81
10 Day1853.62
20 Day1853.78

50 Day1813.62
100 Day1852.62
300 Day1892.34

Epigral Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Ami Organics
1106.5
17
1.56
1321.75
507.23
4541.58

Sudarshan Chemicals Industries
1022.3
-34.25
-3.24
1235
681
7972.14

Epigral
1750.2
-71.15
-3.91
2408.35
1107.45
7569.57

Privi Speciality Chemicals
1975
-46.2
-2.29
2044.55
1040.25
7757.28

Rashtriya Chemicals And Fertil
138
-0.6
-0.43
245
108.05
7613.29

Epigral Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

05-May-25
Audited Results & Final Dividend

27-Jan-25
Quarterly Results & Interim Dividend

09-Nov-24
Quarterly Results

14-Aug-24
To consider Fund Raising

24-Jul-24
Quarterly Results

22-Apr-24
Audited Results & Final Dividend

24-Jan-24
Quarterly Results

06-Nov-23
Quarterly Results

05-Aug-23
Quarterly Results

25-Apr-23
Audited Results & Final Dividend

Meeting Date
Announced on
Purpose

19-May-25
15-Apr-25
POM

18-Sept-24
19-Aug-24
POM

09-Jul-24
12-Jun-24
AGM

29-Jul-23
27-Jun-23
POM

27-Jun-23
05-Jun-23
AGM

14-Mar-22
11-Feb-22
POM

Announced on
Record Date
Ex-Dividend
Dividend Value

27-Jan-25
07-Feb-25
07-Feb-25
2.5

22-Apr-24
02-Jul-24
02-Jul-24
5

25-Apr-23
20-Jun-23
20-Jun-23
2.5

19-Jan-23
01-Feb-23
01-Feb-23
2.5

View All

Company Profile

ABOUT Epigral

Industry Chemical Manufacturing
ISIN INE071N01016
BSE Code 543332
NSE Code MFL

Epigral Limited, formerly Meghmani Finechem Limited, is an India-based manufacturer of essential chemicals. The Company is engaged in manufacturing and selling chlor alkali and its derivatives. It is also engaged in the trading of agrochemical products. The Company manufactures a range of products, such as chlorinated polyvinyl chloride (CPVC) resin, caustic soda, caustic potash, chlorine, hydrogen, chloromethanes, chlorotoluene, and others. The Company operates in single segment, which primarily relates to manufacturing of Chlor Alkali & its Derivatives. The Company’s products are used in alumina, textile, refineries, pharmaceutical, agrochemicals, paper & pulp, soaps & detergent, and other industries. The Company’s subsidiary includes Meghmani Advanced Sciences Limited.

MANAGEMENT

Maulik Patel Chairman of the Board, Managing Director
Sanjay Jain Chief Financial Officer
Gaurang Trivedi Compliance Officer, Company Secretary
Kaushal Soparkar Executive Director

EPIGRAL SUMMARY

Epigral is trading 3.91% lower at Rs 1750.20 as compared to its last closing price. Epigral has been trading in the price range of 1813.90 & 1750.20. Epigral has given -3.87% in this year & -6.54% in the last 5 days.

Epigral has TTM P/E ratio 22.82 as compared to the sector P/E of 17.23. There are 1 analysts who have initiated coverage on Epigral. There are 1 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.

The company posted a net profit of 103.63 Crores in its last quarter.

Listed peers of Epigral include Ami Organics (1.56%), Sudarshan Chemicals Industries (-3.24%), Epigral (-3.91%) etc.

Epigral has a 68.95% promoter holding & 31.05% public holding.

FAQs about Epigral

Epigral is trading at 1750.20 as on 30 Apr, 2025 1:19:50 PM. This is -3.91% lower as compared to its previous closing price of 1821.35

The market capitalization of Epigral is 7569.57 Cr as on 30 Apr, 2025 1:19:50 PM.

The average broker rating on Epigral is Strong Buy. The breakup of analyst rating is given below -

0.00 analysts have given a strong sell rating
0.00 analysts have given a sell rating
0.00 analysts have given a hold rating
0.00 analysts have given a buy rating
1 analysts have given a strong buy rating

The 52 wk high for Epigral is 2408.35 whereas the 52 wk low is 1107.45

Epigral can be analyzed on the following key metrics -

TTM P/E: 22.82
Sector P/E: 17.23
Dividend Yield: 0.41%
D/E ratio: -

Epigral reported a net profit of 195.87 Cr in 2024.

Epigral Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Epigral Share Price

Price Range

Price Range

Key Metrics

Epigral Analysis

Epigral News

Multibagger Stock: Epigral yields 120% return in a year, 430% in over 3 years

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy

Epigral Q1 Results Live : profit rise by 172.54% YOY

Stocks to buy in May: Nirmal Bang suggests Epigral and Suryoday SFB

Epigral Financials

Forecast

Forecast

Forecast

Epigral Technical

Epigral Peers

Epigral Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Epigral

MANAGEMENT

EPIGRAL SUMMARY

FAQs about Epigral

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue